Alfarafisa Nayla Majeda, Chou Yoan, Santika Resti, Riestiano Betha Egih, Soedjana Hardisiswo, Syamsunarno Mas Rizky A A
Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Jatinangor, West Java, Indonesia.
Metabolic in Medicine Working Group Study, Faculty of Medicine, Universitas Padjadjaran, Bandung, West Java, Indonesia.
Clin Cosmet Investig Dermatol. 2025 May 27;18:1309-1337. doi: 10.2147/CCID.S511067. eCollection 2025.
Pathological scars, including hypertrophic, keloid, and atrophic scars, remain challenging to treat, with current therapies offering limited success. Adipose-derived stem cell (ADSC) products, classified into cell-based therapies (stromal vascular fraction [SVF], ADSCs) and cell-free therapies (adipose tissue extract [ATE], secretomes, exosomes, extracellular vesicles), have emerged as potential treatments.
This review examines the therapeutic potential of ADSC products for pathological scars in preclinical and clinical trials, aiming to bridge the gap between experimental research and clinical application. The effectiveness of ADSC products as monotherapies and in combination with other treatments has also been explored.
A comprehensive literature search followed the PICO framework, utilizing electronic databases such as PubMed and Scopus. Original research articles, including both preclinical and clinical trials, were included.
This review included 43 studies that demonstrated the potential of ADSC products to improve pathological scars. ADSC products improve scar texture by regulating ECM, promoting adipogenesis and angiogenesis, and reducing inflammation in hypertrophic and keloid scars. In addition, ADSC products also prevented collagen degradation in atrophic scars. Although their effectiveness varied, ADSC products also showed potential when combined with treatments such as fractional CO laser, PRP, botulinum toxin, and photo-modulation.
ADSC products show promise in treating pathological scars, with varying effectiveness in monotherapy or combination therapy.
病理性瘢痕，包括增生性瘢痕、瘢痕疙瘩和萎缩性瘢痕，治疗仍然具有挑战性，目前的治疗方法成效有限。脂肪来源干细胞（ADSC）产品已成为潜在的治疗方法，可分为基于细胞的疗法（基质血管成分[SVF]、ADSCs）和无细胞疗法（脂肪组织提取物[ATE]、分泌组、外泌体、细胞外囊泡）。
本综述探讨了ADSC产品在临床前和临床试验中治疗病理性瘢痕的潜力，旨在弥合实验研究与临床应用之间的差距。还探讨了ADSC产品作为单一疗法以及与其他治疗方法联合使用时的有效性。
按照PICO框架进行全面的文献检索，利用PubMed和Scopus等电子数据库。纳入了包括临床前和临床试验在内的原始研究文章。
本综述纳入了43项研究，这些研究证明了ADSC产品改善病理性瘢痕的潜力。ADSC产品通过调节细胞外基质、促进脂肪生成和血管生成以及减轻增生性瘢痕和瘢痕疙瘩中的炎症来改善瘢痕质地。此外，ADSC产品还可防止萎缩性瘢痕中的胶原蛋白降解。尽管其有效性各不相同，但ADSC产品与分次二氧化碳激光、富血小板血浆（PRP）、肉毒杆菌毒素和光调制等治疗方法联合使用时也显示出潜力。
ADSC产品在治疗病理性瘢痕方面显示出前景，在单一疗法或联合疗法中的有效性各不相同。
